GE医疗集团5.8亿美元收购癌症诊断公司Clarient Inc(CLRT)

 


美国企业通用电气公司（GE）宣布，同意以约5.8亿美元现金价格收购肿瘤诊断公司Clarient。

通用电气CEO Jeffrey Immelt 在一次新闻发布会上发表讲话GE医疗集团（GE Healthcare）将向Clarient发出收购要约，以5美元/股普通股以及20美元/股优先股的价格收购其全部股份。

"将Clarient的领先技术加入到我们的组合当中，将加速我们在癌症诊断和治疗选择工具领域的扩张，并有力地加强我们目前的诊断和生命科学产品。" GE Healthcare的总裁兼CEO John Dineen周五表示。

Dineen说，GE Healthcare 预计其2010年的强劲增长将持续到明年。

通用电气表示，癌症分析产品和服务的全球需求预计将从2009年的150亿美元上升到2015年的470亿美元。

预计该交易将于2010年底或2011年初完成。

Clarient公司2009年营收增长24%，至9160万美元，该公司开发乳腺癌、前列腺癌、肺癌和结肠癌以及白血病/淋巴瘤等的专有同伴诊断测试。Clarient成立于1996年，最初名字是MicroVision Medical Systems，后改名为ChromaVision。

Clarient网站显示，该公司目前的市场规模约为20亿美元，预计明年将增长6%到10%，2012年将增长至逾30亿美元。

Clarient总部位于加州，是Safeguard公司的合作伙伴公司。后者预计净销售收入约为1.45亿美元。Safeguard拥有充分摊薄-可转换的基础上的26%的Clarient流通股股权，

Safeguard Scientifics公司为创业和创新的生命科学和技术公司提供成长资金，其目标公司的资金需求上限为2500万美元。

本月初，通用电气同意以30亿美元收购私有的能源基础设施服务提供商德莱赛公司（Dresser Inc.），以扩张其能源业务。

在该并购交易中，高盛公司将担任Clarient的财务顾问，而摩根大通银行将担任GE Healthcare的财务顾问。

周四，通用电气股价收于16.10美元。周五盘前交易中，Clarient的股价上涨近35%和Safeguard Scientifics股价上涨了2.2%。

GE Healthcare to Acquire Cancer Diagnostic Company Clarient‎
GE Healthcare, a unit of General Electric Company (NYSE:GE), and Clarient, Inc. (NASDAQ: CLRT) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector. Clarient’s technology, combined with GE Healthcare’s strengths in diagnostic imaging, is expected to accelerate the development of new integrated tools for the diagnosis and characterization of cancer. 

This press kit contains press materials, audio files and pictures in relation with the announcement. 

Important Additional Information
The tender offer described in this webpage has not yet commenced, and this information is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, General Electric Company will cause its indirect, wholly-owned subsidiary, Crane Merger Sub, Inc., to file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (“SEC”). Potential investors and Clarient stockholders are strongly advised to read the tender offer statement (which will include an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by Clarient with the SEC because they will contain important information about the tender offer. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Crane Merger Sub, Inc. at GE Healthcare, 9900 W Innovation Drive, Wauwatosa, WI 53226, Attention: “Corporate Counsel - Business Development”. Potential investors and Clarient stockholders may also read and copy any reports, statements and other information filed by GE, Crane Merger Sub or Clarient with the SEC, at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 or visit the SEC’s website for further information on its public reference room.

Press Contact:

Val Jones
+44 149 449 8052
val.jones@ge.com